Breaking News Instant updates and real-time market news.

2020-11-24 16:03:41 MESA Mesa Air $6.10 / +0.62 (+11.31%) , AAL American Airlines $14.80 / +1.24 (+9.14%) 16:03 11/24/20 11/24 16:03 11/24/20 16:03	Mesa Air enters new contract with American Airlines to operate 40 CRJ-900s Mesa Air (MESA) announced that it has finalized a new contract, which replaces the previous agreement with American Airlines (AAL), to operate 40 CRJ-900s for a five-year term beginning January 1, 2021 through December 31, 2025. Under the previous contract 30 CRJ-900 aircraft were set to expire in 2021 with an additional 17 expiring in 2022. "I want to express my appreciation to the American Eagle team leaders who worked with us on this new contract," said Jonathan Ornstein, chairman and CEO of Mesa Air Group. "This new contract will position Mesa for long term stability and improved performance on our American operation. This year has been difficult for our entire industry, but I'm thankful that despite the obstacles, American has chosen to continue its long-standing relationship with Mesa." MESA Mesa Air $6.10 / +0.62 (+11.31%) AAL American Airlines $14.80 / +1.24 (+9.14%)	04 Dec 09 Dec 23 Jun 10 Nov
MESA AAL MESA Mesa Air $6.10 / +0.62 (+11.31%) 08/11/20 Fly Intel: Top five analyst upgrades 08/11/20 Deutsche Bank Mesa Air upgraded to Buy after earnings at Deutsche Bank 08/11/20 Deutsche Bank Mesa Air upgraded to Buy from Hold at Deutsche Bank 05/11/20 Raymond James Mesa Air downgraded to Outperform from Strong Buy at Raymond James AAL American Airlines $14.80 / +1.24 (+9.14%) 11/18/20 William Blair Boeing 737 Max approval 'a modest positive' for ViaSat, says William Blair 11/17/20 Jefferies American Airlines initiated with an Underperform at Jefferies 11/12/20 Exane BNP Paribas American Airlines initiated with a Neutral at Exane BNP Paribas 10/13/20 Fly Intel: Top five analyst downgrades

2020-11-24 16:03:41

MESA

Mesa Air

$6.10 / +0.62 (+11.31%)

, AAL

American Airlines

$14.80 / +1.24 (+9.14%)

16:03

11/24/20

11/24

16:03

11/24/20

16:03

Mesa Air enters new contract with American Airlines to operate 40 CRJ-900s

Mesa Air (MESA) announced that it has finalized a new contract, which replaces the previous agreement with American Airlines (AAL), to operate 40 CRJ-900s for a five-year term beginning January 1, 2021 through December 31, 2025. Under the previous contract 30 CRJ-900 aircraft were set to expire in 2021 with an additional 17 expiring in 2022. "I want to express my appreciation to the American Eagle team leaders who worked with us on this new contract," said Jonathan Ornstein, chairman and CEO of Mesa Air Group. "This new contract will position Mesa for long term stability and improved performance on our American operation. This year has been difficult for our entire industry, but I'm thankful that despite the obstacles, American has chosen to continue its long-standing relationship with Mesa."

MESA

Mesa Air

$6.10 / +0.62 (+11.31%)

AAL

American Airlines

$14.80 / +1.24 (+9.14%)

04
Dec
09
Dec

23
Jun
10
Nov

MESA
AAL

MESA Mesa Air

$6.10 / +0.62 (+11.31%)

08/11/20: Fly Intel: Top five analyst upgrades

08/11/20 Deutsche Bank: Mesa Air upgraded to Buy after earnings at Deutsche Bank

08/11/20 Deutsche Bank: Mesa Air upgraded to Buy from Hold at Deutsche Bank

05/11/20 Raymond James: Mesa Air downgraded to Outperform from Strong Buy at Raymond James

AAL American Airlines

$14.80 / +1.24 (+9.14%)

11/18/20 William Blair: Boeing 737 Max approval 'a modest positive' for ViaSat, says William Blair

11/17/20 Jefferies: American Airlines initiated with an Underperform at Jefferies

11/12/20 Exane BNP Paribas: American Airlines initiated with a Neutral at Exane BNP Paribas

10/13/20: Fly Intel: Top five analyst downgrades

TODAY'S FREE FLY STORIES

Hot Stocks	Philips' Stellarex drug-coated balloon meets safety goals in two studies » 07:42 01/25/21 01/25 07:42 01/25/21 07:42 PHG Philips $55.60 / +0.22 (+0.40%) Royal Philips announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events PHG Philips $55.60 / +0.22 (+0.40%) 05:22 Today Philips, Rennes University Hospital announce five-year partnership 05:13 Today Philips, Vithas Group enter five-year innovation and collaboration agreement 01/19/21 Philips to acquire Capsule Technologies for $635M in cash, sees accretion 01/14/21 Philips. Merck partner on personalized fertility treatment solutions PHG Philips $55.60 / +0.22 (+0.40%) 07:03 Today Morgan Stanley iRhythm price target raised to $288 from $227 at Morgan Stanley 01/20/21 Berenberg Philips price target raised to EUR 50 from EUR 49 at Berenberg 01/19/21 JPMorgan Philips price target raised to EUR 44 from EUR 39.40 at JPMorgan 11/12/20 Berenberg Philips price target raised to EUR 49 from EUR 46 at Berenberg PHG Philips $55.60 / +0.22 (+0.40%) 05:32 Today Philips reports Q4 adjusted EPS EUR 0.94 vs. EUR 0.83 last year 10/19/20 Philips reports Q3 adj. EPS EUR 0.60 vs. EUR 0.46 last year PHG Philips $55.60 / +0.22 (+0.40%) 01/05/21 Philips shortlists Asian suitors in home appliance unit sale, Bloomberg says PHG Philips $55.60 / +0.22 (+0.40%) 12/18/20 Fly Intel: Wall Street's top stories for Friday 12/18/20 Fly Intel: Wall Street's top stories at midday 10/19/20 Fly Intel: Pre-market Movers 09/05/20 Week in review: How Trump's policies moved stocks 03/02/21 2021 London Global Healthcare Virtual Conference 16:00 Today Philips - PHG
Earnings	OptimizeRx sees 2020 revenue approx. $43M, consensus $37.99M » 07:41 01/25/21 01/25 07:41 01/25/21 07:41 OPRX OptimizeRx $44.66 / +1.63 (+3.79%) Up 75% over 2019.… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 12/07/20 OptimizeRx, Komodo Health partner to expand life sciences support 12/01/20 OptimizeRx launches AI-powered, real-world evidence solution for PoC platform 11/11/20 OptimizeRx appoints Angelo Campano as SVP, principal of agency channels 09/15/20 OptimizeRx expands direct-to-patient reach in partnership with Epion Health OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 01/07/21 Lake Street OptimizeRx price target raised to $40 from $26 at Lake Street 01/07/21 Roth Capital OptimizeRx price target raised to $70 from $40 at Roth Capital 01/04/21 B. Riley Securities OptimizeRx price target raised to $50 from $34 at B. Riley Securities 11/11/20 B. Riley Securities OptimizeRx price target raised to $34 from $30 at B. Riley Securities OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 07:40 Today OptimizeRx sees Q4 revenue approx. $16M, consensus $11.1M 11/09/20 OptimizeRx reports Q3 EPS 7c, consensus 4c 10/20/20 OptimizeRx sees Q3 revenue exceeding $10M, consensus $9.77M 10/13/20 OptimizeRx sees Q3 revenue exceeding $10M, consensus $9.1M OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 10/08/20 OptimizeRx falls after Seeking Alpha contributor sees 'inaccurate financials' 03/15/21 33rd Annual Roth Virtual Conference
Hot Stocks	Axon to change Nasdaq symbol to 'AXON,' effective January 26 » 07:41 01/25/21 01/25 07:41 01/25/21 07:41 AAXN Axon $170.40 / +7.83 (+4.82%) , AXON Axon $0.00 / + (+0.00%) Axon announced that its… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly AAXN AAXN Axon $170.40 / +7.83 (+4.82%) 07:37 Today Axon to change Nasdaq symbol to 'AXON,' effective January 26 01/15/21 Los Angeles Police Department renews contract with Axon 01/12/21 DEA to negotiate on sole source basis with Axon for body worn cameras 12/16/20 Axon to equip Green Bay police with body and in-car cameras and Taser devices AAXN AXON AAXN Axon $170.40 / +7.83 (+4.82%) 01/15/21 Fly Intel: Top five analyst upgrades 01/15/21 Morgan Stanley Axon upgraded to Overweight on new market penetration at Morgan Stanley 01/15/21 Morgan Stanley Axon upgraded to Overweight from Equal Weight at Morgan Stanley 12/16/20 JMP Securities Axon cut to Market Perform at JMP Securities, sees stock as fairly valued AXON Axon $0.00 / + (+0.00%) AAXN AAXN Axon $170.40 / +7.83 (+4.82%) 11/05/20 Axon raises FY20 revenue to $630M-$640M from $625M-$635M, consensus $611.77M 11/05/20 Axon sees Q4 revenue $175M-$185M, consensus 08/06/20 Axon reports Q2 non-GAAP EPS 1c, consensus 16c 17 Jun AAXN AAXN Axon $170.40 / +7.83 (+4.82%) 10/29/20 Justice Department to lift ban on body cameras when working with feds, WSJ says AAXN AAXN Axon $170.40 / +7.83 (+4.82%) 01/15/21 Accolade upgrade, Spotify downgrade among today's top calls on Wall Street 01/15/21 Fly Intel: Pre-market Movers
Hot Stocks	The9 signs investment agreement with Jianping Kong, others » 07:41 01/25/21 01/25 07:41 01/25/21 07:41 NCTY The9 $11.13 / +2.08 (+22.98%) , CAN Canaan $4.86 / +0.07 (+1.46%) The9 (NCTY) signed the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News On The Fly Options NCTY CAN NCTY The9 $11.13 / +2.08 (+22.98%) 07:39 Today The9 signs MOUs on purchase of Bitcoin mining machines 01/04/21 The9 signs term sheet with mining investors to start cryptocurrencies business 11/17/20 The9 receives noncompliance notice from Nasdaq 11/03/20 The9 regains compliance with NASDAQ listing rules CAN Canaan $4.86 / +0.07 (+1.46%) 01/04/21 The9 signs term sheet with mining investors to start cryptocurrencies business 09/08/20 Canaan approves $10M share repurchase program 08/04/20 Canaan announces departure of directors Jianping Kong, Qifeng Sun 08/04/20 Canaan appoints four independent directors to board NCTY CAN NCTY The9 $11.13 / +2.08 (+22.98%) 01/04/21 Fly Intel: Wall Street's top stories for Monday 01/04/21 Fly Intel: Wall Street's top stories at midday 01/04/21 Fly Intel: Pre-market Movers CAN Canaan $4.86 / +0.07 (+1.46%) 11/19/20 Rising High: An exclusive talk with multi-state operator Orchid Ventures 09/08/20 Fly Intel: Pre-market Movers CAN CAN Canaan $4.86 / +0.07 (+1.46%) 01/06/21 Fifteen new option listings on January 6th
Earnings	OptimizeRx sees Q4 revenue approx. $16M, consensus $11.1M » 07:40 01/25/21 01/25 07:40 01/25/21 07:40 OPRX OptimizeRx $44.66 / +1.63 (+3.79%) Up 117% versus the fourth… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals Events OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 12/07/20 OptimizeRx, Komodo Health partner to expand life sciences support 12/01/20 OptimizeRx launches AI-powered, real-world evidence solution for PoC platform 11/11/20 OptimizeRx appoints Angelo Campano as SVP, principal of agency channels 09/15/20 OptimizeRx expands direct-to-patient reach in partnership with Epion Health OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 01/07/21 Lake Street OptimizeRx price target raised to $40 from $26 at Lake Street 01/07/21 Roth Capital OptimizeRx price target raised to $70 from $40 at Roth Capital 01/04/21 B. Riley Securities OptimizeRx price target raised to $50 from $34 at B. Riley Securities 11/11/20 B. Riley Securities OptimizeRx price target raised to $34 from $30 at B. Riley Securities OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 11/09/20 OptimizeRx reports Q3 EPS 7c, consensus 4c 10/20/20 OptimizeRx sees Q3 revenue exceeding $10M, consensus $9.77M 10/13/20 OptimizeRx sees Q3 revenue exceeding $10M, consensus $9.1M 08/05/20 OptimizeRx reports Q2 EPS 2c, consensus (3c) OPRX OptimizeRx $44.66 / +1.63 (+3.79%) 10/08/20 OptimizeRx falls after Seeking Alpha contributor sees 'inaccurate financials' 03/15/21 33rd Annual Roth Virtual Conference

Periodicals	Arrowhead files IND for study of ARO-ANG3 for treatment of mixed dyslipidemia » 07:40 01/25/21 01/25 07:40 01/25/21 07:40 ARWR Arrowhead $82.12 / +2.01 (+2.51%) Arrowhead Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options ARWR Arrowhead $82.12 / +2.01 (+2.51%) 11/25/20 Arrowhead, Takeda Pharmaceutical close collaboration and license agreement 11/13/20 Arrowhead reports presentation of new clinical data at AHA 2020 11/13/20 Arrowhead announces interim clinical data from AROAAT2002 trial 10/13/20 Arrowhead's Mauro Ferrari sells 10,000 common shares ARWR Arrowhead $82.12 / +2.01 (+2.51%) 12/21/20 Baird Arrowhead near-term risks move Baird to the sidelines 12/21/20 Baird Arrowhead downgraded to Neutral from Outperform at Baird 12/15/20 UBS Arrowhead initiated with a Buy at UBS 11/24/20 RBC Capital Arrowhead price target raised to $80 from $62 at RBC Capital ARWR Arrowhead $82.12 / +2.01 (+2.51%) 11/23/20 Arrowhead reports FY20 EPS (84c), consensus (21c) 08/05/20 Arrowhead reports Q3 EPS (13c), consensus (12c) ARWR Arrowhead $82.12 / +2.01 (+2.51%) 07:39 Today Arrowhead files IND for study of ARO-ANG3 for treatment of mixed dyslipidemia ARWR Arrowhead $82.12 / +2.01 (+2.51%) 12/14/20 Fly Insider: Molecular Templates, AMD among notable insider trades 11/23/20 Fly Intel: After-Hours Movers 09/16/20 Fly Intel: Wall Street's top stories for Wednesday 09/16/20 Fly Intel: Wall Street's top stories at midday 02/04/21 Arrowhead - ARWR ARWR Arrowhead $82.12 / +2.01 (+2.51%) 11/23/20 Arrowhead options imply 6.2% move in share price post-earnings
Hot Stocks	Parsons to lead industry team to work with U.S. Air Forces in Europe and Africa » 07:39 01/25/21 01/25 07:39 01/25/21 07:39 PSN Parsons $38.55 / +0.35 (+0.92%) , LDOS Leidos $112.18 / +2.84 (+2.60%) , SAIC SAIC $101.05 / +1 (+1.00%) Parsons (PSN) announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events PSN LDOS SAIC PSN Parsons $38.55 / +0.35 (+0.92%) 12/28/20 Parsons selected for bridge expertise on Illinois projects totaling over $16M 12/17/20 Parsons awarded $20M task order 12/09/20 Parsons awarded $21M contract by Southern Nevada Water Authority 12/08/20 Parsons awarded $32M contract by San Bernardino County Transportation Authority LDOS Leidos $112.18 / +2.84 (+2.60%) 12/15/20 Leidos awarded FAA contract valued at up to $64M 12/10/20 Leidos to acquire IT and cloud solutions provider 1901 Group for $215M 11/23/20 Leidos awarded $82M contract by Naval Medical Logistics Command 11/17/20 3M awarded a contract by Leidos for U.S. DOD DHMSM initiative SAIC SAIC $101.05 / +1 (+1.00%) 11/05/20 SAIC names Prabu Natarajan CFO 11/04/20 SAIC wins spot on USDA contract for IT to farm and conservation agencies 10/29/20 SAIC wins $737M U.S. Air Force modeling, support services contract 10/26/20 SAIC awarded $750M task order from the Army National Guard PSN LDOS SAIC PSN Parsons $38.55 / +0.35 (+0.92%) 05/05/20 Wells Fargo Parsons price target raised to $39 from $33 at Wells Fargo 04/15/20 Benchmark Parsons initiated with a Buy at Benchmark 04/02/20 Wells Fargo Parsons price target lowered to $33 from $42 at Wells Fargo 03/30/20 William Blair Parsons initiated with an Outperform at William Blair LDOS Leidos $112.18 / +2.84 (+2.60%) 11/03/20 Credit Suisse Leidos price target lowered to $120 from $131 at Credit Suisse 09/23/20 Barclays Barclays upgrades Leidos to Overweight, sees above peer growth in 2021 09/23/20 Barclays Leidos upgraded to Overweight from Equal Weight at Barclays 09/22/20 JPMorgan Leidos upgraded to Overweight on bottomed estimates at JPMorgan SAIC SAIC $101.05 / +1 (+1.00%) 09/24/20 William Blair William Blair uncovers second large, unannounced contract win for SAIC 09/16/20 William Blair SAIC seems to have won 8th largest contract at $753M, says William Blair 09/08/20 JPMorgan SAIC removed from Analyst Focus List at JPMorgan 09/03/20 Citi SAIC price target raised to $105 from $100 at Citi PSN LDOS SAIC PSN Parsons $38.55 / +0.35 (+0.92%) 11/04/20 Parsons backs FY20 revenue view $3.95B-$4.05B, consensus $4.01B 11/04/20 Parsons reports Q3 adj. EPS 57c, consensus 33c 08/05/20 Parsons backs FY20 revenue view $3.95B-$4.05B, consensus $4.02B 08/05/20 Parsons reports Q2 adj. EPS 49c, consensus 29c LDOS Leidos $112.18 / +2.84 (+2.60%) 11/02/20 Leidos raises FY20 adjusted EPS view to $5.65-$5.85 from $5.25-$5.55 11/02/20 Leidos reports Q3 adjusted EPS $1.47, consensus $1.23 08/04/20 Leidos raises FY20 EPS view to $5.25-$5.55 from $5.00-$5.30, consensus $5.24 08/04/20 Leidos reports Q2 EPS $1.55, consensus $1.09 SAIC SAIC $101.05 / +1 (+1.00%) 12/03/20 SAIC narrows FY21 adj. EPS view to $5.95-$6.05 from $5.80-$6.10 12/03/20 SAIC reports Q3 adjusted EPS $1.62, consensus $1.53 09/02/20 SAIC backs FY21 adjusted EPS view $5.80-$6.10, consensus $6.13 09/02/20 SAIC reports Q2 adjusted EPS $1.63, consensus $1.44 PSN SAIC PSN Parsons $38.55 / +0.35 (+0.92%) 11/16/20 Fly Insider: Cerevel Therapeutics, Paylocity among weeks notable insider trades SAIC SAIC $101.05 / +1 (+1.00%) 09/02/20 Fly Intel: After-Hours Movers 02/09/21 42nd Annual Aerospace/Defense & Industrials Virtual Conference 02/23/21 Leidos - LDOS 02/24/21 Parsons - PSN
Periodicals	Arrowhead files IND for study of ARO-ANG3 for treatment of mixed dyslipidemia » 07:39 01/25/21 01/25 07:39 01/25/21 07:39 ARWR Arrowhead $82.12 / +2.01 (+2.51%) Arrowhead Pharmaceuticals… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options ARWR Arrowhead $82.12 / +2.01 (+2.51%) 11/25/20 Arrowhead, Takeda Pharmaceutical close collaboration and license agreement 11/13/20 Arrowhead reports presentation of new clinical data at AHA 2020 11/13/20 Arrowhead announces interim clinical data from AROAAT2002 trial 10/13/20 Arrowhead's Mauro Ferrari sells 10,000 common shares ARWR Arrowhead $82.12 / +2.01 (+2.51%) 12/21/20 Baird Arrowhead near-term risks move Baird to the sidelines 12/21/20 Baird Arrowhead downgraded to Neutral from Outperform at Baird 12/15/20 UBS Arrowhead initiated with a Buy at UBS 11/24/20 RBC Capital Arrowhead price target raised to $80 from $62 at RBC Capital ARWR Arrowhead $82.12 / +2.01 (+2.51%) 11/23/20 Arrowhead reports FY20 EPS (84c), consensus (21c) 08/05/20 Arrowhead reports Q3 EPS (13c), consensus (12c) ARWR Arrowhead $82.12 / +2.01 (+2.51%) 12/14/20 Fly Insider: Molecular Templates, AMD among notable insider trades 11/23/20 Fly Intel: After-Hours Movers 09/16/20 Fly Intel: Wall Street's top stories for Wednesday 09/16/20 Fly Intel: Wall Street's top stories at midday 02/04/21 Arrowhead - ARWR ARWR Arrowhead $82.12 / +2.01 (+2.51%) 11/23/20 Arrowhead options imply 6.2% move in share price post-earnings
Hot Stocks	The9 signs MOUs on purchase of Bitcoin mining machines » 07:39 01/25/21 01/25 07:39 01/25/21 07:39 NCTY The9 $11.13 / +2.08 (+22.98%) The9 announced that it… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News On The Fly NCTY The9 $11.13 / +2.08 (+22.98%) 01/04/21 The9 signs term sheet with mining investors to start cryptocurrencies business 11/17/20 The9 receives noncompliance notice from Nasdaq 11/03/20 The9 regains compliance with NASDAQ listing rules 09/21/20 The9, Voodoo to collaborate on game publishing in mainland China NCTY The9 $11.13 / +2.08 (+22.98%) 01/04/21 Fly Intel: Wall Street's top stories for Monday 01/04/21 Fly Intel: Wall Street's top stories at midday 01/04/21 Fly Intel: Pre-market Movers
Recommendations	Kansas City Southern price target raised to $246 from $237 at Credit Suisse » 07:39 01/25/21 01/25 07:39 01/25/21 07:39 KSU Kansas City Southern / + Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options KSU Kansas City Southern / + 01/20/21 Kansas City Southern, NorthPoint to develop Wylie Logistics Park in Texas 01/20/21 North American rail traffic rose 8.6% in the week ended January 16 01/14/21 North American rail traffic rose 3% in the week ended January 9 01/07/21 North American rail traffic rose 1.3% in the week ended January 2 KSU Kansas City Southern / + 07:28 Today Benchmark Kansas City Southern transferred at Benchmark with unchanged Hold rating 07:19 Today Morgan Stanley Kansas City Southern price target raised to $200 from $142 at Morgan Stanley 07:11 Today Barclays Kansas City Southern price target raised to $235 from $220 at Barclays 01/15/21 Raymond James Kansas City Southern price target raised to $245 from $210 at Raymond James KSU Kansas City Southern / + 01/22/21 Kansas City Southern sees FY22 EPS $10.50-$11.00 01/22/21 Kansas City Southern sees FY21 EPS at least $9.00, consensus $8.51 01/22/21 Kansas City Southern reports Q4 EPS $1.80, consensus $1.92 01/21/21 Notable companies reporting before tomorrow's open KSU Kansas City Southern / + 11/10/20 Kansas City Southern potential bidders have moved on, CNBC reports 09/09/20 Kansas City Southern rejects $20B buyout bid from PE suitors, WSJ says 09/09/20 Kansas City Southern rejects $20B buyout bid from PE suitors, WSJ says 09/02/20 Blackstone, GIP make bid to buy Kansas City Southern, WSJ says KSU Kansas City Southern / + 09/10/20 Fly Intel: Wall Street's top stories for Thursday 09/10/20 Fly Intel: Wall Street's top stories at midday 09/09/20 Fly Intel: After-Hours Movers 09/02/20 Fly Intel: Wall Street's top stories for Wednesday 02/09/21 42nd Annual Aerospace/Defense & Industrials Virtual Conference KSU Kansas City Southern / + 07/31/20 Kansas City Southern bid could be valued over $21B with debt, WSJ reports

Initiation	KemPharm initiated with a Buy at Roth Capital » 07:39 01/25/21 01/25 07:39 01/25/21 07:39 KMPH KemPharm $6.06 / +0.07 (+1.17%) Roth Capital analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Events Options KMPH KemPharm $6.06 / +0.07 (+1.17%) 01/14/21 KemPharm announces presentations on KP415, serdexmethylphenidate 12/23/20 KemPharm announces 1-for-16 reverse stock split 12/22/20 KemPharm files IND for KP879 for treatment of stimulant use disorder 11/18/20 KemPharm, Corium to host investor event on KP415 strategy KMPH KemPharm $6.06 / +0.07 (+1.17%) 05/20/20 H.C. Wainwright KemPharm price target lowered to $1.50 from $2.50 at H.C. Wainwright 03/02/21 PDUFA Date for KP415 KMPH KemPharm $6.06 / +0.07 (+1.17%) 01/21/21 Eighteen new option listings and one option delisting on January 21st 12/21/20 Four new option listings and fifteen option delistings on December 21st
Hot Stocks	Arbutus Biopharma sees cash runway into mid-2022 » 07:38 01/25/21 01/25 07:38 01/25/21 07:38 ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) Arbutus had approximately… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 07:37 Today Arbutus Biopharma announces 2021 corporate objectives 12/10/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 11/16/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 11/05/20 Arbutus Biopharma expects cash to fund operations into mid-2022 ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 12/17/20 H.C. Wainwright Arbutus Biopharma initiated with a Buy at H.C. Wainwright 09/15/20 Chardan Arbutus HBV data 'could represent a turning point,' says Chardan 07/27/20 B. Riley FBR Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/24/20 Baird Arbutus Biopharma upside priced in, Baird downgrades to Neutral ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 11/05/20 Arbutus Biopharma reports Q3 EPS (27c), consensus (22c) 08/07/20 Arbutus Biopharma reports Q2 EPS (25c), consensus (24c) ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 08/07/20 Fly Intel: Pre-market Movers ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 12/15/20 Arbutus Biopharma call buyer realizes 80% same-day gains 08/18/20 Largest borrow rate increases among liquid names
Hot Stocks	Everbridge awarded statewide vaccine distribution deployment in West Virginia » 07:37 01/25/21 01/25 07:37 01/25/21 07:37 EVBG Everbridge $141.63 / -3.09 (-2.14%) Everbridge announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings EVBG Everbridge $141.63 / -3.09 (-2.14%) 01/13/21 Everbridge says Mass Notification system to be used in DC 01/06/21 Everbridge receives 'important' new patent related to its Public Warning system 10/12/20 Everbridge appoints John Maeda as chief customer experience officer 09/01/20 Everbridge, Sequential Technology International announce partnership EVBG Everbridge $141.63 / -3.09 (-2.14%) 01/15/21 Credit Suisse Everbridge downgraded to Neutral at Credit Suisse as Shah assumes coverage 01/15/21 Credit Suisse Everbridge downgraded to Neutral from Outperform at Credit Suisse 11/06/20 Canaccord Everbridge price target raised to $180 from $170 at Canaccord 10/28/20 BofA Everbridge downgraded to Neutral from Buy at BofA EVBG Everbridge $141.63 / -3.09 (-2.14%) 11/05/20 Everbridge raises 2020 EPS outlook to (3c)-(1c) from (12c)-(9c) 11/05/20 Everbridge sees Q4 EPS 1c-3c, consensus 11c 11/05/20 Everbridge reports Q3 EPS 5c, consensus (11c) 08/06/20 Everbridge sees FY20 adjusted EPS (12c)-(9c), consensus (18c)
Hot Stocks	Arbutus Biopharma announces 2021 corporate objectives » 07:37 01/25/21 01/25 07:37 01/25/21 07:37 ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) Summary of 2021 Corporate… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 12/10/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 11/16/20 Arbutus Biopharma announces additional HBsAg decline data with AB-729 11/05/20 Arbutus Biopharma expects cash to fund operations into mid-2022 09/15/20 Arbutus Biopharma announces AB-729 90 mg single-dose week 12 data in HBV ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 12/17/20 H.C. Wainwright Arbutus Biopharma initiated with a Buy at H.C. Wainwright 09/15/20 Chardan Arbutus HBV data 'could represent a turning point,' says Chardan 07/27/20 B. Riley FBR Arbutus Biopharma price target raised to $8 from $6 at B. Riley FBR 07/24/20 Baird Arbutus Biopharma upside priced in, Baird downgrades to Neutral ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 11/05/20 Arbutus Biopharma reports Q3 EPS (27c), consensus (22c) 08/07/20 Arbutus Biopharma reports Q2 EPS (25c), consensus (24c) ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 08/07/20 Fly Intel: Pre-market Movers ABUS Arbutus Biopharma $4.04 / +0.08 (+2.02%) 12/15/20 Arbutus Biopharma call buyer realizes 80% same-day gains 08/18/20 Largest borrow rate increases among liquid names
Recommendations	Lam Research price target raised to $650 from $450 at Credit Suisse » 07:37 01/25/21 01/25 07:37 01/25/21 07:37 LRCX Lam Research $563.92 / -0.27 (-0.05%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options LRCX Lam Research $563.92 / -0.27 (-0.05%) 12/02/20 Lam Research VP Vahid Vahedi sells almost $1.3M in company shares 11/16/20 Lam Research CFO sells 8.2K shares of common stock 11/05/20 Lam Research announces $5B share repurchase authorization, quarterly dividend 08/27/20 Lam Research raises quarterly dividend 13% to $1.30 per share LRCX Lam Research $563.92 / -0.27 (-0.05%) 07:02 Today Deutsche Bank Lam Research price target raised to $575 from $500 at Deutsche Bank 06:38 Today Citi Citi moves Marvell up to pick in semiconductor equipment 06:30 Today Citi Lam Research price target raised to $660 from $420 at Citi 01/18/21 Goldman Sachs Lam Research price target raised to $616 from $557 at Goldman Sachs LRCX Lam Research $563.92 / -0.27 (-0.05%) 10/21/20 Lam Research sees Q2 EPS $5.60, +/- 40c, consensus $5.16 10/21/20 Lam Research reports Q1 EPS $5.67, consensus $5.19 10/21/20 Notable companies reporting after market close 07/29/20 Lam Research sees Q3 EPS $5.15 +/- 40c, consensus $4.14 LRCX Lam Research $563.92 / -0.27 (-0.05%) 09/28/20 SMIC, China's biggest chipmaker, facing U.S. sanctions, FT reports LRCX Lam Research $563.92 / -0.27 (-0.05%) 12/28/20 Kinnate initiations, Nikola target change among today's top calls on Wall Street 07/29/20 Fly Intel: After-Hours Movers 02/11/21 Technology & Internet Virtual Conference 01/27/21 Lam Research - LRCX LRCX Lam Research $563.92 / -0.27 (-0.05%) 11/27/20 Early notable gainers among liquid option names on November 27th 10/06/20 Lam Research call volume above normal and directionally bullish 09/24/20 Early notable gainers among liquid option names on September 24th 09/02/20 Lam Research call volume above normal and directionally bullish

Hot Stocks	CVS Health administered first round of COVID-19 vaccine doses » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 CVS CVS Health $74.11 / +0.04 (+0.05%) CVS Health has… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Options CVS CVS Health $74.11 / +0.04 (+0.05%) 01/11/21 CVS Health names Laurie Havanec as Chief People Officer 01/06/21 CVS Health names Michelle Peluso as first-ever Chief Customer Officer 01/06/21 CVS Health: No COVID-19 vaccines currently available at CVS Pharmacy locations 01/06/21 CVS Health administering COVID-19 vaccines in SNF's in 49 states CVS CVS Health $74.11 / +0.04 (+0.05%) 01/22/21 Baird Tabula Rasa HealthCare may have lost MTM deal at Aetna, says Baird 01/19/21 JPMorgan Teladoc remains top 2021 healthcare technology pick at JPMorgan 01/08/21 Fly Intel: Top five analyst upgrades 01/08/21 Jefferies CVS Health upgraded to Buy on COVID-19 vaccination upside at Jefferies CVS CVS Health $74.11 / +0.04 (+0.05%) 11/06/20 CVS Health raises FY20 adj. EPS view to $7.35-$7.45 from $7.14-$7.27 11/06/20 CVS Health reports Q3 adj. EPS $1.66, consensus $1.33 11/05/20 Notable companies reporting before tomorrow's open 11/05/20 Notable companies reporting before tomorrow's open CVS CVS Health $74.11 / +0.04 (+0.05%) 01/02/21 Coca-Cola, Disney among value stocks deserving a fresh look, Barron's says 12/20/20 CDC panel says frontline workers, people over 74 should be next, NYTimes reports 11/20/20 Trump to release new rules aimed at lowering drug prices, WSJ reports 11/10/20 Supreme Court appears unlikely to topple ACA, USA Today says CVS CVS Health $74.11 / +0.04 (+0.05%) 12/01/20 Fly Intel: What to watch in Salesforce's earnings report 11/17/20 Fly Intel: Wall Street's top stories at midday 11/17/20 Pharmacy owners, suppliers slide after Amazon launches new offerings 11/17/20 Fly Intel: Pre-market Movers CVS CVS Health $74.11 / +0.04 (+0.05%) 01/11/21 CVS Health call volume above normal and directionally bullish 11/17/20 Unusually active option classes on open November 17th 11/10/20 CVS Health call volume above normal and directionally bullish 11/06/20 Early notable gainers among liquid option names on November 6th
Earnings	City Holding reports Q4 EPS $1.40, consensus $1.08 » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 CHCO City Holding $71.53 / +0.68 (+0.96%) The Company's net… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings CHCO City Holding $71.53 / +0.68 (+0.96%) 12/16/20 City Holding raises quarterly dividend to 58c from 57c per share CHCO City Holding $71.53 / +0.68 (+0.96%) 09/24/20 Boenning & Scattergood City Holding resumed with a Neutral at Boenning & Scattergood 07/09/20 Piper Sandler City Holding resumed with a Neutral at Piper Sandler CHCO City Holding $71.53 / +0.68 (+0.96%) 10/22/20 City Holding reports Q3 EPS $1.25, consensus 88c
Hot Stocks	Kimberly-Clark sees FY21 Share repurchases of $650M-$750M 07:35 01/25/21 01/25 07:35 01/25/21 07:35 KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 07:35 Today Kimberly-Clark announces 6.5% increase in quarterly dividend to $1.14 per share 07:33 Today Kimberly-Clark sees FY21 CapEx $1.2B-$1.3B 07:32 Today Kimberly-Clark announces 6.5% increase in quarterly dividend 07:31 Today Kimberly-Clark announces new $5B share repurchase program KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 01/21/21 Deutsche Bank Kimberly-Clark price target lowered to $144 from $150 at Deutsche Bank 01/19/21 Bernstein Kimberly-Clark initiated with a Market Perform at Bernstein 12/07/20 Wells Fargo Kimberly-Clark initiated with an Underweight at Wells Fargo 10/16/20 Fly Intel: Top five analyst initiations KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 07:33 Today Kimberly-Clark sees FY21 adjusted EPS $7.75-$8.00, consensus $7.77 07:30 Today Kimberly-Clark reports Q4 adjusted EPS $1.69, consensus $1.60 10/22/20 Kimberly-Clark raises FY20 net sales growth view to 2%-3% from 1%-2% 10/22/20 Kimberly-Clark raises FY20 adj. EPS view to $7.50-$7.65 from $7.40-$7.60 KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 12/08/20 Lowe's upgrade, Coca-Cola initiation among today's top calls on Wall Street 10/22/20 Fly Intel: Wall Street's top stories for Thursday 10/22/20 Fly Intel: Wall Street's top stories at midday 10/22/20 Fly Intel: Pre-market Movers 10:00 Today Kimberly-Clark - KMB
Hot Stocks	MacroGenics' Margenza meets survival endpoint in Phase 3 breast cancer trial » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 MGNX MacroGenics $22.55 / +0.23 (+1.03%) MacroGenics announced the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events MGNX MacroGenics $22.55 / +0.23 (+1.03%) 12/18/20 MacroGenics, Janssen enter research collaboration for DART molecule 12/16/20 FDA okays MacroGenics' Margenza in combo therapy with chemo in breast cancer 12/07/20 MacroGenics presents results from dose expansion study of tebotelimab 12/06/20 MacroGenics presents flotetuzumab data in patients with refractory AML MGNX MacroGenics $22.55 / +0.23 (+1.03%) 12/22/20 H.C. Wainwright MacroGenics assumed with a Buy at H.C. Wainwright 12/17/20 Barclays MacroGenics price target raised to $14 from $8 at Barclays 08/03/20 Citi MacroGenics downgraded to Neutral from Buy at Citi 06/02/20 Citi MacroGenics price target raised to $25 from $15 at Citi MGNX MacroGenics $22.55 / +0.23 (+1.03%) 11/04/20 MacroGenics reports Q3 EPS (66c), consensus (93c) 07/30/20 MacroGenics reports Q2 EPS (94c), consensus (92c) MGNX MacroGenics $22.55 / +0.23 (+1.03%) 12/16/20 Fly Intel: After-Hours Movers 03/01/21 41st Annual Healthcare Virtual Conference
Earnings	OFG Bancorp reports Q4 EPS 42c, two estimates 45c » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 OFG OFG Bancorp $19.19 / + (+0.00%) Reports Q4 core revenue… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Earnings Events OFG OFG Bancorp $19.19 / + (+0.00%) 10/23/20 OFG Bancorp reports Q3 EPS 50c, consensus 35c 10:00 Today OFG Bancorp - OFG

Hot Stocks	Kimberly-Clark announces 6.5% increase in quarterly dividend to $1.14 per share » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) The quarterly dividend… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 07:33 Today Kimberly-Clark sees FY21 CapEx $1.2B-$1.3B 07:32 Today Kimberly-Clark announces 6.5% increase in quarterly dividend 07:31 Today Kimberly-Clark announces new $5B share repurchase program 01/06/21 Columbia Sportswear names Starbucks' John Culver to board of directors KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 01/21/21 Deutsche Bank Kimberly-Clark price target lowered to $144 from $150 at Deutsche Bank 01/19/21 Bernstein Kimberly-Clark initiated with a Market Perform at Bernstein 12/07/20 Wells Fargo Kimberly-Clark initiated with an Underweight at Wells Fargo 10/16/20 Fly Intel: Top five analyst initiations KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 07:33 Today Kimberly-Clark sees FY21 adjusted EPS $7.75-$8.00, consensus $7.77 07:30 Today Kimberly-Clark reports Q4 adjusted EPS $1.69, consensus $1.60 10/22/20 Kimberly-Clark raises FY20 net sales growth view to 2%-3% from 1%-2% 10/22/20 Kimberly-Clark raises FY20 adj. EPS view to $7.50-$7.65 from $7.40-$7.60 KMB Kimberly-Clark $132.24 / +1.14 (+0.87%) 12/08/20 Lowe's upgrade, Coca-Cola initiation among today's top calls on Wall Street 10/22/20 Fly Intel: Wall Street's top stories for Thursday 10/22/20 Fly Intel: Wall Street's top stories at midday 10/22/20 Fly Intel: Pre-market Movers 10:00 Today Kimberly-Clark - KMB
Hot Stocks	Abeona to enroll 10 to 15 patients in Phase 3 VIITAL study following FDA meeting » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 ABEO Abeona Therapeutics $2.11 / +0.125 (+6.30%) Abeona Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ABEO Abeona Therapeutics $2.11 / +0.125 (+6.30%) 12/21/20 Abeona announces acceptance of late-breaker abstracts for WORLDSymposium 10/27/20 Abeona Therapeutics names of Michael Amoroso as COO 10/06/20 Abeona forms special committee to oversee strategic direction, leadership, ops 09/28/20 Abeona Therapeutics exploring all strategic options, alternatives ABEO Abeona Therapeutics $2.11 / +0.125 (+6.30%) 11/25/20 H.C. Wainwright Abeona Therapeutics price target lowered to $8 from $11 at H.C. Wainwright 11/11/20 B. Riley Securities Abeona Therapeutics price target raised to $3 from $2 at B. Riley Securities 11/10/20 Cantor Fitzgerald Cantor upgrades Abeona to Overweight with shares trading near cash 11/10/20 Cantor Fitzgerald Abeona Therapeutics upgraded to Overweight from Neutral at Cantor Fitzgerald ABEO Abeona Therapeutics $2.11 / +0.125 (+6.30%) 11/09/20 Abeona Therapeutics reports Q3 EPS (8c), consensus (15c) 08/10/20 Abeona Therapeutics reports Q2 EPS (14c), consensus (17c) 02/08/21 17th Annual Virtual WORLDSymposium 2021
Recommendations	Morgan Stanley price target raised to $84 from $74 at Credit Suisse » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 MS Morgan Stanley $74.13 / -0.57 (-0.76%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MS Morgan Stanley $74.13 / -0.57 (-0.76%) 01/22/21 Morgan Stanley director sells 29K shares of common stock 01/22/21 Morgan Stanley CFO sells 18.9K shares of common stock 01/22/21 Morgan Stanley CEO sells 175K shares of common stock 01/20/21 Morgan Stanley expects net new assets to remain above historical levels MS Morgan Stanley $74.13 / -0.57 (-0.76%) 01/21/21 DA Davidson Morgan Stanley price target raised to $90 from $80 at DA Davidson 01/21/21 Barclays Morgan Stanley price target raised to $95 from $88 at Barclays 01/21/21 RBC Capital Morgan Stanley price target raised to $78 from $55 at RBC Capital 01/20/21 BMO Capital Morgan Stanley price target raised to $81 from $78 at BMO Capital MS Morgan Stanley $74.13 / -0.57 (-0.76%) 01/20/21 Morgan Stanley reports Q4 EPS $1.81, consensus $1.27 01/19/21 Notable companies reporting before tomorrow's open 01/19/21 Notable companies reporting before tomorrow's open 01/18/21 Fly Intel: What to watch in next round of big banks' earnings reports MS Morgan Stanley $74.13 / -0.57 (-0.76%) 01/05/21 Oatly planning 2021 initial public offering, CNBC reports 12/31/20 M&A activity rebounded into year-end to finish 2020 down just 5%, FT says 12/22/20 Tech companies win as SEC permits direct IPOs for cash raise, Bloomberg says 12/22/20 'James Bond' studio MGM Holdings exploring sale, WSJ reports MS Morgan Stanley $74.13 / -0.57 (-0.76%) 01/20/21 Fly Intel: Wall Street's top stories for Wednesday 01/20/21 Fly Intel: Wall Street's top stories at midday 01/20/21 Fly Intel: Pre-market Movers 11/10/20 Square, Wayfair upgrades among today's top calls on Wall Street 02/24/21 22nd Annual Virtual Financial Services Forum MS Morgan Stanley $74.13 / -0.57 (-0.76%) 01/15/21 Unusual call flow in option market yesterday 01/14/21 $1.3M call seller in Morgan Stanley opens two week position into earnings 01/12/21 Unusual call flow in option market yesterday 01/11/21 Diagonal call spread in Morgan Stanley rolls $16M premium position
Options	Unusual call flow in option market yesterday » 07:35 01/25/21 01/25 07:35 01/25/21 07:35 F Ford $11.52 / -0.005 (-0.04%) Notable call activity was… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return in 9 minutes Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options F Ford $11.52 / -0.005 (-0.04%) 01/21/21 Ford sees 2020 underfunded status for pension of about $6.7B 01/21/21 Ford to replace Takata airbag inflators in certain models at cost of $610M 01/19/21 EU passenger car registrations down 3.3% in December 01/11/21 Ford to stop manufacturing in Brazil, sees pre-tax special item charges of $4.1B F Ford $11.52 / -0.005 (-0.04%) 01/22/21 JPMorgan JPMorgan upgrades Ford to Overweight ahead of 'hot new products' 01/22/21 JPMorgan Ford upgraded to Overweight from Neutral at JPMorgan 01/20/21 Deutsche Bank Ford price target raised to $11 from $9 at Deutsche Bank 01/20/21 Deutsche Bank Ford named 'Catalyst Call: Buy Idea' at Deutsche Bank F Ford $11.52 / -0.005 (-0.04%) 10/28/20 Ford sees temporarily lower F-150 wholesale shipments in Q4 10/28/20 Ford reports Q3 adjusted EBIT $3.6B 10/28/20 Ford reports Q3 adjusted EPS 65c, consensus 16c 10/28/20 Notable companies reporting after market close F Ford $11.52 / -0.005 (-0.04%) 01/19/21 Amazon and Ford backed EV Truck-maker Rivian raises another $2.65B, WSJ says 01/08/21 Ford to idle Kentucky plant, blames microchip shortage, Detroit News reports 01/05/21 Rivian close to raising funds at $25B valuation, Bloomberg says 01/05/21 Rivian close to raising funds at $25B valuation, Bloomberg says F Ford $11.52 / -0.005 (-0.04%) 01/23/21 Charged: Oppenheimer ups Tesla target to Street-high $1,036 01/22/21 Fly Intel: Wall Street's top stories for Friday 01/22/21 Fly Intel: Wall Street's top stories at midday 01/22/21 Disney, Ford upgrades among today's top calls on Wall Street 02/04/21 Ford - F F Ford $11.52 / -0.005 (-0.04%) 01/22/21 September risk reversal in Ford suggests bullish medium-term view 01/22/21 Notable open interest changes for January 22nd 01/22/21 Unusual call flow in option market yesterday 01/21/21 Ford call volume off to the races as shares and implied volatility surge
Recommendations	Ultragenyx price target raised to $99 from $64 at Credit Suisse » 07:33 01/25/21 01/25 07:33 01/25/21 07:33 RARE Ultragenyx $140.45 / +7.35 (+5.52%) Credit Suisse analyst… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return tomorrow Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Events RARE Ultragenyx $140.45 / +7.35 (+5.52%) 01/21/21 Ultragenyx announces FDA clearance of IND application for UX701 01/11/21 Ultragenyx announces 2021 milestones 01/11/21 Ultragenyx reports cash, cash equivalents $1.2B as of Dec. 31 01/11/21 Ultragenyx sees 2021 Crysvita revenue $180M-$190M RARE Ultragenyx $140.45 / +7.35 (+5.52%) 01/11/21 Baird Ultragenyx price target raised to $165 from $110 at Baird 01/11/21 Barclays Ultragenyx price target raised to $176 from $121 at Barclays 01/08/21 Piper Sandler Ultragenyx price target raised to $165 from $108 at Piper Sandler 12/07/20 Fly Intel: Top five analyst downgrades RARE Ultragenyx $140.45 / +7.35 (+5.52%) 10/27/20 Ultragenyx reports Q3 EPS ($1.13), consensus ($1.27) 07/30/20 Ultragenyx sees FY20 Crysvita revenue $125M-$140M 07/30/20 Ultragenyx reports Q2 EPS 41c, consensus ($1.54) 29 Oct 02/08/21 17th Annual Virtual WORLDSymposium 2021 03/01/21 41st Annual Healthcare Virtual Conference

Events

Earnings calls, analyst events, roadshows and more

Today at 08:30

Chicago Fed National Activity Index: December 2020 Government Event
Today at 08:30

Chicago Fed National Activity Index--3 Month Moving Average: December 2020 Government Event
CADE
Today at 08:30

Cadence Bancorp - CADE Conference Calls
SMG
Today at 09:00

The Scotts Miracle-Gro Company Firm Sponsored Meetings
KMB
Today at 10:00

Kimberly-Clark - KMB Conference Calls
OFG
Today at 10:00

OFG Bancorp - OFG Conference Calls
Today at 10:30

Dallas Fed Manufacturing Survey--General Activity Index: January 2021 Government Event
Today at 10:30

Dallas Fed Manufacturing Survey Production Index: January 2021 Government Event
FRBK
Today at 11:00

Republic First Bancorp - FRBK Conference Calls
CBU
Today at 11:00

Community Bank System - CBU Conference Calls

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	AGFY X AGFY Agrify IPO Managers: Maxim & Roth Capital $8.00-10.00 2.8M Shares
Tues	SHLS X SHLS Shoals Technologies IPO Managers: Goldman Sachs, JPMorgan, Guggenheim, UBS, Morgan Stanley, Barclays & Credit Suisse, Cowen, Oppenheimer $19.00-21.00 50M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial
Wed	OCDX X OCDX Ortho Clinical IPO Managers: JPMorgan, BofA, Goldman Sachs, Barclays & Morgan Stanley, Citi, Credit Suisse, UBS, Evercore ISI, Piper Sandler, ING Bank, Macquarie, Nomura, TCG Capital Markets, Drexel Hamilton, H.C. Wainwright, Ramirez, Seibert Williams $20.00-23.00 70M Shares Special Comments Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial VINP X VINP Vinci Partners Investments IPO Managers: JPMorgan, Goldman Sachs & BTG Pactual, Itau BBA, BofA, Credit Suisse, UBS $16.00-18.00 13.873M Shares Special Comments Ratings Some content is locked. Log in above or sign up for a free trial to see this information. Get Free Trial XM X XM Qualtrics IPO Managers: Morgan Stanley & JPMorgan, BofA, Barclays, Deutsche Bank, Goldman Sachs, HSBC, Citi, BMO Capital, Truist, Canaccord, Evercore ISI, JPMorgan, Oppenheimer, Piper Sandler, Raymond James, William Blair, Loop Capital, RMRZ, SEEL $22.00-26.00 49.2M Shares ZIM X ZIM ZIM Integrated IPO Managers: Citi, Goldman Sachs & Barclays, Jefferies, Clarksons Platou $16.00-19.00 17.5M Shares
Thurs	SEGR X SEGR Southeastern Grocers IPO Managers: BofA & Goldman Sachs, Deutsche Bank, BMO Capital, Truist, Wells Fargo $14.00-16.00 8.9M Shares
Fri	No deals

View All Syndicate Announcements »

Mesa Air enters new contract with American Airlines to operate 40 CRJ-900s

TODAY'S FREE FLY STORIES

Get Full Fly Access